GDUFA: How Much Does FDA Know About U.S. Generic Market After Facility Self-Identification?
Executive Summary
Agency continues to analyze facility data following generic drug facility fee announcement; some fees were higher than anticipated after fewer manufacturing plants registered than expected. But industry believes the count is accurate and illustrates the influence of foreign manufacturers.
You may also be interested in...
GDUFA II: Inspection Information Takes Center Stage
Sponsors say transparency is important as generic drug user fee negotiations move to inspection policy.
GDUFA Self-Identification Woes Can’t Deflate Industry, FDA Enthusiasm
As the grace period nears its close, industry officials say they expected problems getting generic drug manufacturing facilities to self-identify under the new user fee requirement; meanwhile, FDA expects to hire nearly three times the staff in the Office of Generic Drugs to meet GDUFA commitments.
FDASIA Is Signed, Not That White House Wanted Anyone To Notice
White House sends out short press release as FDA is conducting an unrelated briefing to announce the user fee bill was enacted, surprising stakeholders and generating political questions.